LC-MS/MS method for determining amikacin in human plasma
| Nominal concentration (μg/ml) | |||
| 0.4 | 4 | 40 | |
| Intra-day precession (n=5) | |||
| Mean±SD | 0.42±0.03 | 3.89±0.26 | 41.54±2.07 |
| RSD (%) | 6.79 | 6.76 | 4.98 |
| RE (%) | 5.75 | −2.70 | 3.85 |
| Inter-day precession (n=15, 3 days) | |||
| Mean±SD | 0.41±0.04 | 3.91±0.39 | 40.05±3.02 |
| RSD (%) | 10.08 | 9.91 | 7.55 |
| RE (%) | 2.25 | −2.25 | 0.13 |
| % recovery (n=5) | |||
| Mean±SD | 100.75±9.12 | 93.02±12.51 | 98.77±7.45 |
| % matrix effect (n=5) | |||
| Mean±SD | 113.23±12.26 | 96.70±8.56 | 106.45±6.45 |
| Freeze and thaw stability (n=5) | |||
| Mean±SD | 0.38±0.03 | 4.39±0.04 | 41.34±2.02 |
| RSD (%) | 8.19 | 0.91 | 4.89 |
| RE (%) | −5.60 | 9.65 | 3.35 |
| Post-preparative stability (48 hours at 4℃) (n=5) | |||
| Mean±SD | 0.43±0.03 | 4.43±0.17 | 42.88±2.21 |
| RSD (%) | 6.12 | 3.74 | 5.15 |
| RE (%) | 6.65 | 10.70 | 7.20 |
| Stability for 12 hours at room temperature (n=5) | |||
| Mean±SD | 0.44±0.01 | 4.23±0.18 | 40.60±2.41 |
| RSD (%) | 2.29 | 4.36 | 5.94 |
| RE (%) | 9.65 | 5.80 | 1.50 |
LC-MS/MS, liquid chromatography-tandem mass spectrometry; RE, relative error; RSD, relative SD.